Heart safety check for experimental liver drug
NCT ID NCT07263152
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested whether a single dose of hydronidone, an experimental drug for liver fibrosis, changes the heart's electrical activity (QTc interval) in 48 healthy Chinese adults. Participants received one of three doses or a placebo, and researchers measured how the drug affected their heart rhythm over time. The goal was to check safety, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hydronidone capsules
What this could lead to
If successful, this study could help determine a safe dose range for hydronidone in future trials for liver fibrosis.
What could go wrong
This is an early-phase safety study in healthy people, not patients. It only looks at heart rhythm effects, not whether the drug works for liver disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Gobroad Hospital
Beijing, China